GW Pharmaceuticals in advanced epilepsy trials for CBD rich cannabis concentrate
Above, cannabis oil produced from CBD-rich cannabis
GW Pharmaceuticals, with their Sativex product have one of the few internationally legal cannabis concentrates available. Sativex is a 1:1 THC:CBD oral spray which is used mainly for treatment of MS related symptoms. Their next product is another cannabis extract and is called Epidiolex, its a CBD-dominant concentrate used for treatment of drug resistant epilepsy. The cannabis community already know that CBD can be used to stop epileptic fits, but the formal Stage 3 ‘double blind’ clinical trials will be welcomed by many people keen to see just how effective cannabis is in dealing with epilepsy. Children with Dravets syndrome in the USA are already using cannabis oil in Colorado (extracted from the CDB-dominant Charlottes Web variety). In the new trials people with Lennox-Gastaut syndrome will be assessed with the CBD-rich Epidiolex.
More information on this story is here http://uk.advfn.com/news/UKREG/2015/article/66800238
June 2nd 2015